Supernus Pharmaceuticals (SUPN) Net Margin (2011 - 2025)
Supernus Pharmaceuticals (SUPN) reported Net Margin of 1.95% for Q4 2025, down 1076.0% year-over-year from 0.2% in Q4 2024, and up 91.68% quarter-over-quarter from 23.49% in Q3 2025.
Supernus Pharmaceuticals (SUPN) Net Margin (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 15 years of Net Margin data on file, last reported at 1.95% in Q4 2025.
- Net Margin for Q4 2025 came in at 1.95%, down 1076.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 5.37% (down 1653.0% YoY), and the FY2025 annual result was 5.36%, down 1652.0% from the prior year.
- Net Margin grew to 1.95% in Q4 2025 per SUPN's latest filing, from 23.49% in the prior quarter.
- Over five years, Net Margin peaked at 21.94% in Q3 2024 and troughed at 23.49% in Q3 2025.
- A 5-year average of 4.92% and a median of 4.47% in 2021 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin surged 3234 bps in 2024, then sank 4542 bps in 2025.
- A 5-year view of Net Margin shows it stood at 1.54% in 2021, then surged by 893 bps to 15.24% in 2022, then tumbled by 95 bps to 0.69% in 2023, then soared by 1172 bps to 8.8% in 2024, then tumbled by 122 bps to 1.95% in 2025.
- Business Quant data shows SUPN's Net Margin at 1.95% in Q4 2025, 23.49% in Q3 2025, and 13.6% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 9.19% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 26.57% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 35.18% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 2.94% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 24.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 4.16% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -168.42% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.15% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 31.38% |
| 10 | Supernus Pharmaceuticals | 2.63 Bn | 2.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.95% |
| Sep 30, 2025 | -23.49% |
| Jun 30, 2025 | 13.60% |
| Mar 31, 2025 | -7.89% |
| Dec 31, 2024 | 8.80% |
| Sep 30, 2024 | 21.94% |
| Jun 30, 2024 | 11.82% |
| Mar 31, 2024 | 0.09% |
| Dec 31, 2023 | 0.69% |
| Sep 30, 2023 | -10.40% |
| Jun 30, 2023 | -0.61% |
| Mar 31, 2023 | 11.00% |
| Dec 31, 2022 | 15.24% |
| Sep 30, 2022 | 0.99% |
| Jun 30, 2022 | 4.60% |
| Mar 31, 2022 | 16.80% |
| Dec 31, 2021 | 1.54% |
| Sep 30, 2021 | 14.52% |
| Jun 30, 2021 | 16.79% |
| Mar 31, 2021 | 4.35% |